

Sheet 1 of 1


SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.	50059/007002	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. §1.98(b))				Serial No.	09/830,400	
				Applicant	Lee Nadler et al.	
				Filing Date	April 25, 2001	
				Group	Not Yet Assigned	
				IDS Filed	May 15, 2001	
				Customer No.	21559	
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
AJ	5,679,647	10/21/97	Carson et al.	X	X	
AJ	5,747,317	05/05/98	Cao			
AJ	5,770,422	06/23/98	Collins			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
AJ	Bohm et al., "Identification of HLA-A2-Restricted Epitopes of the Tumor-Associated Antigen MUC2 Recognized by Human Cytotoxic T Cells," <i>International J. of Cancer</i> 75:688-693 (1998).					
AJ	Brunette et al., "Immunotherapy (Cancer): Tumor Antigen Specific Immunotherapy of Cancer: Peptide and Gene Based Modification of Dendritic Cells as Antigen Presenting Cells," <i>Cancer Biotechnology Weekly</i> p16 (1998).					
AJ	Celis et al., "Identification of Potential CTL Epitopes of Tumor-Associated Antigen MAGE-1 for Five Common HLA-A Alleles," <i>Molecular Immunology</i> 31:1423-1430 (1994).					
AJ	Herlyn et al., "Epitope- and Antigen-Specific Cancer Vaccines," <i>International Review of Immunology</i> 7:245-257 (1991).					
EXAMINER			/Amy Juedes/		DATE CONSIDERED /Amy Juedes/	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						



21559

PATENT, TRADEMARK OFFICE

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE



Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE <div style="text-align: center;"> INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) </div> (37 C.F.R. §1.98(b))				Attorney Docket No. 50059/007002 Serial No. 09/830,400 Applicant Lee M. Nadler et al. Filing Date April 25, 2001 Group Not Yet Assigned IDS Filed July 30, 2001 Customer No. 21559		
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
AJ	WO 98/14593	09.04.98	WIPO			No
AJ	WO 98/37181	27.08.98	WIPO			No
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
 Schultze et al., "Autologous Adoptive T Cell Transfer For A Patient With Plasma Cell Leukemia: Results Of A Pilot Phase I Trial," <i>Therapy of Chronic Lymphocytic Leukemia And Multiple Myeloma</i> p. 109a Poster Board#/Session 446-I. 						
 Vonderheide et al., "The Telomerase Catalytic Subunit Is a Widely Expressed Tumor-associated Antigen Recognized By Cytotoxic T Lymphocytes," <i>Immunity</i> 10:673-679 (1999). 						
EXAMINER			DATE CONSIDERED			
/Amy Juedes/			09/21/2006			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						

Please type a plus sign (+) in this box



Modified Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number

09/830,400

Filing Date

April 25, 2001

First Named Inventor

Nadler, et al.

Group Art Unit

1642

Examiner Name

Not Yet Assigned

Attorney Docket Number

20363-015 NATL

FEB 19 2003

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. PATENT DOCUMENTS

TECH CENTER 1600/2900

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date mm/dd/yyyy	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate mm/dd/yyyy

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication mm/dd/yyyy	Translation Yes No
	B3	EP 1 093 381	Norsk Hydro ASA	04/25/2001	
AJ	B4	WO 99/50392	Geron Corp.	10/07/1999	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
AJ	C7	Brossart, et al. (1998). "Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes." <i>Cancer Research</i> . 58(4):732-736.
	C8	Jensen, et al. (1998). "A europium fluoroimmunoassay for measuring peptide binding to MHC class I molecules." <i>Journal of Immunological Methods</i> . 215(1-2):71-80.
	C9	Kawashima, et al. (1998). "The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors." <i>Human Immunology</i> . 59(1):1-14.
	C10	Kim, et al. (1994). "Specific association of human telomerase activity with immortal cells and cancer." <i>Science</i> . 266:2011-2015.
	C11	Schultze, et al. (1997). "CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy." <i>Journal of Clinical Investigation</i> . 100(11):2757-2765.
	C12	Schultze, et al. (1997). "Vaccination as immunotherapy for B cell lymphoma." <i>Hematological Oncology</i> . 15(3):129-139.
AJ	C13	Vonderheide, et al. (1999). "Generation of telomerase-specific HLA-A3-restricted cytotoxic T lymphocytes from patient blood: implications for widely applicable anti-cancer immunotherapy." <i>Forty-first annual meeting of the American Society of Hematology</i> , New Orleans. 94(10):677a.
	C14	Supplementary Partial European Search Report for Application No. EP 89 05 6777. Mailed on 11/11/2002.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Amy Juedes/	Date Considered	09/21/2006
-----------------------	--------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.